[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
July 26, 2016

Whole Brain Radiotherapy for Brain MetastasesIs the Debate Over?

Author Affiliations
  • 1Department of Radiation Oncology, University of North Carolina at Chapel Hill
  • 2Division of Medical Oncology, Department of Medicine, University of North Carolina at Chapel Hill
  • 3Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
  • 4Department of Neurosurgery, University of North Carolina at Chapel Hill
JAMA. 2016;316(4):393-395. doi:10.1001/jama.2016.8692

There has been ongoing debate regarding the value of stereotactic radiosurgery (SRS) alone compared with SRS plus whole brain radiation therapy (WBRT) for patients who have limited metastatic lesions in the brain. In this issue of JAMA, Brown and colleagues report the results of a randomized clinical trial (RCT) in which 213 patients with 1 to 3 brain metastases all less than 3 cm in diameter were randomized to either SRS alone or SRS plus WBRT.1 Compared with SRS plus WBRT, there was less cognitive deterioration at 3 months after SRS alone (63.5% [40/63 patients] vs 91.7% [44/48]; difference, 28.2%; 90% CI, 14.%-41.9%) and better quality of life (mean change from baseline, −0.1 vs −12.0 points; mean difference, −11.9 points; 95% CI, −19 to −14.8 points). In contrast, intracranial disease control rates (local and distant) at 3 months were 93.7% (89/95) with SRS plus WBRT and 75.3% (79/105) with SRS alone, a mean difference of 18.4% (95% CI, 7.8%-29.0%). Median overall survival was similar in the 2 groups (SRS alone, 10.4 months; SRS plus WBRT, 7.4 months; hazard ratio, 1.02; 95% CI, 0.75-1.38).

First Page Preview View Large
First page PDF preview
First page PDF preview